“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.
In this video, Daniel P. Petrylak, MD, PhD, discusses major takeaways and ongoing research in urothelial cancer, which was presented on at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Petrylak is the director of genitourinary oncology, a professor of medicine and urology, co-leader of Cancer Signaling Networks, and co-director of the Signal Transduction Program at the Yale University Cancer Center in New Haven, Connecticut.
EV-302 data on EV/pembro in urothelial carcinoma published in NEJM
March 7th 2024Data showed that the combination of EV and pembrolizumab extended overall survival and progression-free survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.